Key facts
- This page summarizes Jason Bradley Terrell MD's Form 4 filing for VOLITIONRX LTD (VNRX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Aug 2022, 16:01.
Jason Bradley Terrell MD - 03 Aug 2022 Form 4 Insider Report for VOLITIONRX LTD (VNRX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VNRX
- Reported as of
- 03 Aug 2022
- Net transaction value
- -$9,226
- SEC form
- 4
- Accepted by SEC
- 05 Aug 2022, 16:01:20 UTC
- Prior SEC filing
- 24 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Bradley Terrell MD
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jason Bradley Terrell MD filed Form 4 for VOLITIONRX LTD (VNRX) on 05 Aug 2022.
Change
- Previous filing in this sequence was filed on 24 Jun 2022.
- Current net transaction value: -$9,226.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
VNRX
transaction
Common Stock
Tax liability
- Transaction value
- $8,430
- Shares
- -4,279
- Change %
- -12%
- Price
- $1.97
- Shares after
- 30,866
- Date
- 03 Aug 2022
- Ownership
- Direct
- Footnotes
- F1
VNRX
transaction
Common Stock
Tax liability
- Transaction value
- $796
- Shares
- -404
- Change %
- -15%
- Price
- $1.97
- Shares after
- 2,326
- Date
- 03 Aug 2022
- Ownership
- By Spouse
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 17,573 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.
Footnote F2
Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the spouse of the reporting person upon settlement of 1,365 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.